World leaders open COP31 summit in Antalya
World leaders began two days of speeches at the COP31 Antalya Leaders Summit on Wednesday, with Turkey pushing an electrification goal and the United States absent for the second year in a row.
Every story, newest first.
World leaders began two days of speeches at the COP31 Antalya Leaders Summit on Wednesday, with Turkey pushing an electrification goal and the United States absent for the second year in a row.
Chris Van Hollen's challenge to Chuck Schumer for Senate majority leader drew formal endorsements from Bernie Sanders and Senator-elect Abdul El-Sayed on Thursday, while Schumer said he has the votes to win the December 1 secret ballot.
UNICEF said on Tuesday that drones travelling up to 1,500 kilometres struck Sudanese power stations on every day of the last week of October, with up to 15 hit in the month, and that armed drones account for two in three child casualties in Sudan this year.
Scholar Rock has agreed to sell the Priority Review Voucher it won with the September approval of Isembyld for 205 million dollars, while its first patients were infused in October and third quarter product revenue came in at 0.6 million dollars.
Mirum's brelovitug met the combined primary endpoint in the Phase 3 AZURE-4 study of chronic hepatitis D, with 59 percent of patients on the weekly dose and 44 percent on the monthly dose achieving virologic response with ALT normalisation at week 24, against none on delayed treatment.
Coherus is cutting about 30 percent of its workforce to focus on esophageal cancer, Vertex will lay off 78 Crinetics staff in San Diego in January, and a former Lilly sales manager has sued over alleged off-label Mounjaro promotion.
The FDA has approved pimicotinib, sold as Pimjetmi, for adults with symptomatic tenosynovial giant cell tumor where surgery could worsen function, after the drug produced a 56 percent response rate against 3 percent on placebo at week 25.
The Netherlands Authority for Consumers and Markets is investigating whether Biogen abused a dominant position by making its Stratify blood test available only to patients on, or considering, its multiple sclerosis drug Tysabri.
Incoming Democratic committee chairs have sent a new round of letters to 27 drugmakers demanding the unredacted text of their most-favored-nation pricing agreements with the Trump administration, according to STAT.
Beam Therapeutics said its one-time base-edited cell therapy risto-cel met the primary endpoint of the BEACON trial, freedom from severe vaso-occlusive crises for at least 12 consecutive months, and that it plans a United States approval filing as early as the end of 2026.